Skip to main content
Premium Trial:

Request an Annual Quote

Personal Genome Diagnostics Gets CE Mark for Elio Tissue Complete Assay

NEW YORK – Personal Genome Diagnostics said today that it has successfully CE marked its PGDx Elio tissue complete assay, allowing the company to provide greater access to precision medicine for cancer patients in the European Union.

The 507-gene, next-generation sequencing panel detects single-nucleotide variants, small insertions and deletions, amplifications, rearrangements, microsatellite instability, and tumor mutational burden in DNA patient tissue samples. The assay is intended to help oncologists guide therapy selection for cancer patients across the spectrum of tumor types.

"With this assay, physicians throughout Europe will be able to secure specific, actionable information that can help them make improved treatment decisions," PGDx CEO Doug Ward said in a statement.

The newly CE-marked tissue assay joins PGDx's liquid biopsy test, called Elio Plasma Resolve, which garnered its own CE mark in March.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.